Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Frequently asked questions
What sector does Achieve Life Sciences, Inc (ACHV) operate in?
Achieve Life Sciences, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Achieve Life Sciences, Inc (ACHV) current stock price?
As of the latest data, Achieve Life Sciences, Inc stock price is $6.54, with a previous close of $6.49. Achieve Life Sciences, Inc gained $0.05 in the last trading session, representing a 0.77% increase.
What is Achieve Life Sciences, Inc (ACHV) current market capitalization?
Achieve Life Sciences, Inc market cap is approximately 672.98 million.
What is Achieve Life Sciences, Inc (ACHV) Earnings Per Share (EPS)?
The trailing EPS is -$1.66, and the forward EPS is -$0.64.
What is Achieve Life Sciences, Inc (ACHV) EBITDA?
Achieve Life Sciences, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -74.43 million.
Does Achieve Life Sciences, Inc (ACHV) pay dividends?
No. Achieve Life Sciences, Inc does not pay a dividend.
When is Achieve Life Sciences, Inc (ACHV) next earnings report?
Achieve Life Sciences, Inc is expected to release its next earnings report on September 30, 2026.
What is Achieve Life Sciences, Inc (ACHV) beta (volatility) score?
Achieve Life Sciences, Inc has a beta of 2.253, indicating very high volatility compared to the market.
